

Rx FOR SUCCESS**Colorectal Cancer**

Colorectal cancer is the third most common cancer in men and women and the third leading cause of cancer death in the United States. Most colorectal cancer arises slowly from an adenomatous polyp over 7 to 15 years. Incidence and mortality rates have been decreasing due to earlier detection and better treatment.

Risk factors for developing colorectal cancer include family history of cancer or polyps, inherited conditions (such as familial adenomatous polyposis and hereditary nonpolyposis), diet, age, inflammatory bowel disease (such as ulcerative colitis or Crohn's disease), and a personal history of polyps. A prior history of colorectal cancer increases the risk of other colon tumors.

The wall of the colon consists of four layers: mucosa (adjacent to the lumen), submucosa, muscularis propria, and serosa (outermost, farthest from the lumen). The prognosis worsens as deeper layers of the colon wall are invaded. Staging of colorectal cancer is based on depth of invasion through these layers and on any spread to other tissues, and is given per the TNM system. The Duke's system is an older staging system.

The table below describes the old and new staging classifications.

STAGE	TNM	DUKE'S	DESCRIPTION
0	Tis, NO, MO		<i>In situ</i> , tumor confined to mucosa
I	T1, NO, MO	A	Tumor through the mucosa into submucosa
I	T2, NO, MO	A	Tumor through submucosa in muscularis propria
IIA	T3, NO, MO	B1	Tumor through muscularis propria and into subserosa but not into neighboring tissues
IIB	T4, NO, MO	B2	Tumor into nearby tissues or organs, but nodes remain negative
IIIA	T1, N1, MO T2, N1, MO	C1	T1 or T2 plus 1 – 3 nodes positive
IIIB	T3, N1, MO T4, N1, MO	C2	T3 or T4 plus 1 – 3 nodes positive
IV	M1	D	Spread to distant sites such as liver, lung, peritoneum, ovary, etc.

A colonoscopy is generally recommended one year after curative resection. If clear of polyps and tumor, the next colonoscopy can be performed in year three, then every five years. Closer surveillance is needed in those at high risk (hereditary syndromes and inflammatory bowel disease).

Ratings will depend on stage and time since the end of treatment. An additional rating or postponement may be necessary if the applicant does not follow surveillance recommendations. The rating table is on the next page.

This material is intended for insurance informational purposes only and is not personal medical advice for clients. Rates and availability will vary based on the satisfaction of our underwriting criteria. Underwriting rules are subject to change at our discretion.

This material is being provided for informational or educational purposes only and does not take into account the investment objectives or financial situation of any clients or prospective clients. The information is not intended as investment advice and is not a recommendation about managing or investing a client's retirement savings. Clients seeking information regarding their particular investment needs should contact a financial professional.

Life Insurance issued by The Prudential Insurance Company of America and its affiliates, Newark, NJ.

NOT FOR CONSUMER USE.

© 2020 Prudential Financial, Inc. and its related entities.
1010832-00002-00 Ed. 10/2020



STAGE	RATING			
	AGE 65 OR YOUNGER AT DIAGNOSIS		AGE OLDER THAN 65 AT DIAGNOSIS	
Carcinoma <i>in situ</i> , Tis	No rating		No rating	
Stage I and Stage IIA	Tumor table C		Tumor table D*	
Stage IIB	Tumor table B		Tumor table C	
Stage III—Best case only with two or fewer positive lymph nodes and normal CEA	0-5 years	Decline	0-2 years	Decline
	6th year	Table B + \$10x5	3rd year	Table B + \$10x5
	7th year	Table B + \$10x4	4th year	Table B + \$10x4
	8th year	Table B + \$10x3	5th year	Table B + \$10x3
	9th year	Table B + \$10x2	6th year	Table B + \$10x2
	10th year	Table B + \$10x1	7th year	Table B + \$10x1
	Thereafter	Table B	Thereafter	Table B
Stage III (More than two lymph nodes positive) and Stage IV	Decline		Decline	

*For Stage T1, N0, M0 only—if diagnosis was at age 70 or older, there is no rating required.

Malignant Tumor Table Rating Schedule

	A	B	C	D
Within 1st year	Decline	Decline	Decline	\$5x3
2nd year	Decline	Decline	\$7.50x5	\$5x2
3rd year	Decline	\$10x6	\$7.50x4	\$5x1
4th year	\$15x6	\$10x5	\$7.50x3	0
5th year	\$15x5	\$10x4	\$7.50x2	0
6th year	\$15x4	\$10x3	\$7.50x1	0
7th year	\$15x3	\$10x2	0	0
8th year	\$15x2	\$10x1	0	0
9th year	\$15x1	0	0	0

For example: Stage 0, colon cancer *in situ* is not rated and would be eligible for Non-Smoker Plus if otherwise qualified. An applicant diagnosed at age 55 with Stage IIB cancer in the third year following treatment would be rated under Tumor Table B: \$10x6.

To get an idea of how a client with a history of Colorectal Cancer would be viewed in the underwriting process, use the Ask “Rx”pert Underwriter on the next page for an informal quote.

Ask "Rx"pert Underwriter (Ask Our Expert)

After reading the *Rx for Success* on Colorectal Cancer, use this form to Ask "Rx"pert Underwriter for an informal quote.

Producer _____ Phone _____ Fax _____
 Client _____ Age/DOB _____ Sex _____

If your client has had Colorectal Cancer, please answer the following:

1. Please list date of diagnosis and send pathological report.

2. How was the cancer treated?

Surgery

Surgery plus chemotherapy and/or radiation

3. Please list date treatment completed.

4. Is your client on any medications?

Yes. Please give details. _____

No

5. What stage was the cancer?

Stage Tis

Stage IIB

Stage I

Stage III

Stage IIA

Stage IV

6. Has there been any evidence of recurrence?

Yes. Please give details. _____

No

7. When was your client's last colonoscopy and CEA level? Please give date and results.

8. Has your client smoked cigarettes in the last 12 months?

Yes. Please give details. _____

No

9. Does your client have any other major health problems (e.g., inflammatory bowel disease, heart disease, etc.)?

Yes. Please give details. _____

No